GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sacituzumab tirumotecan overview

Sacituzumab Tirumotecan  (Jiataile) is a conjugated humanized monoclonal antibody with potential antineoplastic activity. It is formulated as lyophilized powder for solution for intravenous route of administration. Jiataile is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have previously received at least two systemic treatments (at least one of which was for the advanced or metastatic stage).

sacituzumab tirumotecan (SKB-264) is under development for the treatment of ovarian epithelial cancer, gastric adenocarcinoma, triple negative breast cancer, endometrial carcinoma, HER2 negative breast cancer,  HER2-negative gastroesophageal junction adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, colorectal cancer, bile duct cancer, head and neck cancer squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, metastatic cervical cancer, metastatic castration-resistant prostate cancer, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma, non-muscle invasive bladder cancer and Urothelial cancers. It is a third-generation antibody-drug conjugate that acts by targeting cells expressing (trophoblast antigen) TROP2. It is administered through intravenous and intravesical route in the form of powder. The drug candidate is being developed based on the ADC conjugation technology.

It was under development for the treatment of pancreatic ductal adenocarcinoma, colorectal cancer and bladder cancer.

Merck overview

Merck is a biopharmaceutical company that focuses on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for the treatment of cardiovascular conditions, cancer, immune disorders, infectious and respiratory diseases, and diabetes, among others. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors, and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is headquartered in Rahway, New Jersey, the US.

For a complete picture of Sacituzumab tirumotecan’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.